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Patients with tuberous sclerosis complex (TSC) develop hamartomatous tumors showing loss of 
function of the tumor suppressor TSC1 (hamartin) or TSC2 (tuberin) and increased 
angiogenesis, fibrosis, and abundant mononuclear phagocytes. To identify soluble factors with 
potential roles in TSC tumorigenesis, we screened TSC skin tumor–derived cells for altered 
gene and protein expression. Fibroblast-like cells from 10 angiofibromas and five periungual 
fibromas produced higher levels of monocyte chemoattractant protein-1 (MCP-1) mRNA and 
protein than did fibroblasts from the same patient’s normal skin. Conditioned medium from 
angiofibroma cells stimulated chemotaxis of a human monocytic cell line to a greater extent 
than conditioned medium from TSC fibroblasts, an effect blocked by neutralizing MCP-1–
specific antibody. Overexpression of MCP-1 seems to be caused by loss of tuberin function 
because Eker rat embryonic fibroblasts null for 
 
Tsc2
 
 (EEF 
 
Tsc2
 
 
 
/
 
 
 
) produced 28 times as much 
MCP-1 protein as did EEF 
 
Tsc2
 
 
 
/
 
 
 
 cells; transient expression of WT but not mutant human 
 
TSC2
 
 by EEF 
 
Tsc2
 
 
 
/
 
 
 
 cells inhibited MCP-1 production; and pharmacological inhibition of the 
Rheb-mTOR pathway, which is hyperactivated after loss of 
 
TSC2
 
, decreased MCP-1 production 
by EEF 
 
Tsc2
 
 
 
/
 
 
 
 
 
cells. Together these findings suggest that MCP-1 is an important paracrine 
factor for TSC tumorigenesis and may be a new therapeutic target.
 
Patients with tuberous sclerosis complex
(TSC) are predisposed to developing tumors in
the brain, eyes, heart, kidneys, lung, and skin.
Although typically benign, these tumors cause
significant morbidity, including seizures, mental
retardation, and disfigurement. The tendency
to form multiple tumors is a consequence of
inactivating mutations in a tumor-suppressor
gene, either 
 
TSC1
 
 or 
 
TSC2
 
 (1). The products
of these genes, hamartin and tuberin, seem to
function as a complex to regulate many cellular
processes, in particular signaling through the
PI3K-Akt-TSC1/2-Rheb-mTOR pathway (2).
Loss of function of the hamartin-tuberin com-
plex in TSC tumors enhances mTOR signaling
leading to increased cell numbers and cell size.
Skin tumors, including multiple facial an-
giofibromas and periungual fibromas, are ob-
served in 
 
 
 
90% of patients with TSC (3). Histo-
logically, angiofibromas and periungual fibromas
show increased vessels and fibrosis. There are also
increased numbers of cells in the interstitial der-
mis, predominantly spindle-shaped, fibroblast-
like cells together with stellate cells that seem
to be monocyte-derived DCs, based on immu-
noreactivity for factor XIIIa (4–6). These features
are shared variably by TSC tumors in other
organs. Increased angiogenesis is observed in
TSC-associated tumors of the kidney, lung,
and brain (7), and increased numbers of cells
positive for factor XIIIa have been observed in
subependymal giant cell astrocytomas and an-
giomyolipomas (4). More recently, tubers have
been reported to contain increased numbers of
cells expressing CD68, a marker used to identify
cells of the monocyte/macrophage/DC lineage
(8). It has not been determined what induces
the mixture of cell populations composing
these hamartomatous tumors and whether this
cellular heterogeneity is related to loss of
hamartin-tuberin function.
The mixed cellular composition of TSC
tumors points to a role for soluble growth factors
in their development. Prompted by the increased
vascularity of TSC tumors, others have investi-
gated angiogenic factors. TSC tumors of the
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skin, brain, and kidney produce vascular endothelial growth
factor (VEGF) (7, 9, 10). Furthermore, overexpression of
VEGF is related to loss of tuberin function and is at least par-
tially mTOR-dependent (11, 12). It has been proposed that
overexpression of VEGF is a unifying feature of hamartoma
syndromes (13).
To identify soluble growth factors involved in the devel-
opment of TSC skin tumors, we profiled cytokine mRNA
levels and protein production in cultured angiofibroma and
periungual fibroma cells. TSC skin tumor cells overexpressed
MCP-1, a chemokine that stimulates angiogenesis, fibrosis,
and recruitment of monocytes. The relationship between
MCP-1 production and loss of tuberin function was investi-
gated using EEF 
 
Tsc2
 
 
 
/
 
 
 
 cells and pharmacological inhibitors
of the PI3K-Akt-mTOR pathway. These experiments indi-
cate that overexpression of MCP-1 in EEF 
 
Tsc2
 
 
 
/
 
 
 
 cells is
mTOR-dependent and is related to loss of tuberin function.
 
RESULTS
Angiofibromas and periungual fibromas show increased 
vessels, fibrosis, and mononuclear phagocytes
 
Angiofibromas and periungual fibromas contained greater
numbers of dermal cells positive for CD68 than did patient’s
normal-appearing skin (Fig. 1). These positive cells were stellate
or polygonal in shape. As previously reported for angiofibromas
(4–6), more cells positive for factor XIIIa, another marker for
monocyte-derived cells, were seen in angiofibromas and peri-
ungual fibromas than in normal-appearing skin (unpublished
data). As expected, angiofibromas and periungual fibromas had
greater numbers of endothelial cells positive for CD34 and der-
mal cells positive for vimentin than did normal-appearing skin
(unpublished data). There were sparse but elevated numbers of
cells positive for S100 in the papillary dermis, and there were
almost no cells in the dermis positive for HMB-45 (unpub-
lished data). The intensity of staining for smooth muscle actin
was greater in perivascular cells of angiofibromas and periungual
fibromas than in normal-appearing skin (unpublished data).
Thus, increased cellularity in these skin tumors derives from
several cell lineages.
 
Cells cultured from angiofibromas and periungual fibromas 
express fibroblast markers
 
We hypothesized that the abnormal cellular composition of
TSC skin tumors was related to altered expression of soluble
growth factors. To generate an in vitro system for study, cells
were grown from angiofibromas, periungual fibromas, and
the patient’s normal-appearing skin using standard methods
for culturing fibroblasts. Cells grown from angiofibromas and
periungual fibromas were bipolar or multipolar, as previously
reported (14, 15). Immunocytochemistry was used to distin-
guish cells from different lineages, using, for example, an an-
tibody to the collagen chaperone HSP47 to detect fibroblasts
(16). Fibroblasts from normal-appearing skin of a TSC pa-
tient (hereafter referred to as TSC fibroblasts) and angiofi-
broma cells from the same patient expressed HSP47 but not
CD68 (Fig. 2, A–F). They also expressed vimentin but not
CD14, S100, or smooth muscle actin (unpublished data).
 
Angiofibroma and periungual fibroma cells show altered 
expression of soluble growth factors
 
A cytokine cDNA array was used to compare gene expression,
using total RNA from paired cultures of TSC fibroblasts and
angiofibroma cells from three patients. In the studies reported
below, cells were incubated in DMEM plus 1% FBS for 1 d to
reduce extrinsic stimulation of cytokine production, unless
noted otherwise. Four of 268 genes were overexpressed by a
mean of threefold or more, including MCP-1 (9.8-fold), insu-
lin-like growth factor-binding protein 2 (IGFBP2) (8.1-fold),
secreted frizzled-related protein 2 (3.2-fold), and IGFBP5 (3.0-
fold). For VEGF, the mean ratio of tumor to TSC fibroblasts
was 1.4. It is interesting that IGFBP3 expression was reported
in an earlier study of angiofibroma cells (17), and that IGFBP1,
IGFBP2, IGFBP4, IGFBP5, and IGFBP6 are expressed in pul-
monary lesions of lymphangioleiomyomatosis, that also exhibit
mutations in TSC genes (18).
Because changes in mRNA expression are not always re-
flected at the protein level, the levels of MCP-1 and 10
Figure 1. CD68-positive cells are more abundant in TSC skin tumors 
than in normal-appearing skin from a patient with TSC. (A) In sections 
of normal-appearing skin, cells staining for CD68 (brown) are sparse in the 
dermis. Bar, 65  m. (B) In sections of a periungual fibroma, there are 
dilated vessels and fibrosis and a more cellular stroma. Many stromal cells 
stain positive for CD68. Bar, 65  m. (C) CD68-positive cells are located 
near vessels among CD68-negative, fibroblast-like cells. Bar, 15  m. Similar 
results were observed in four angiofibromas and four periungual fibromas 
from six patients. 
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other cytokines (selected based on cDNA array data or po-
tential roles in TSC tumorigenesis) were measured in culture
supernatants using an ELISA array. After 24 h incubation,
only MCP-1 was higher in supernatants from angiofibroma
cells than TSC fibroblasts in all paired samples from seven
patients (P 
 
 
 
 0.018; Fig. 3). Because of the altered expres-
sion observed using both cDNA and ELISA arrays, MCP-1
was selected for further studies.
 
Angiofibroma and periungual fibroma cells overexpress 
MCP-1 capable of stimulating migration of monocytes
 
MCP-1 mRNA levels were quantified using real-time PCR
in cells derived from angiofibromas and periungual fibromas.
Levels of MCP-1 mRNA in angiofibroma cells and periun-
gual fibroma cells were 1.3- to 33-fold (
 
n
 
 
 
 
 
 10, P 
 
 
 
 0.001)
and 1.8- to 4.9-fold (
 
n
 
 
 
 
 
 5, P 
 
 
 
 0.007), respectively, greater
than those in TSC fibroblasts (Table I). MCP-1 protein was
measured using ELISA, and results were normalized to total
cellular ATP levels after demonstrating the same linear rela-
tionship of cell number and cellular ATP in TSC fibroblasts
and angiofibroma cells (unpublished data). Almost all of the
MCP-1 produced was released into the medium, with only
5% recovered in cell lysates (unpublished data). TSC angiofi-
broma cells and periungual fibroma cells released 1.4- to
104-fold (P 
 
 
 
 0.001) and 1.4- to 4.1-fold (P 
 
 
 
 0.015), re-
spectively, as much MCP-1 into the medium as TSC fibro-
blasts (Table I). The fold changes in MCP-1 mRNA corre-
lated with those of MCP-1 protein (
 
n
 
 
 
 
 
 15; Pearson
correlation 
 
 
 
 0.868; P 
 
 
 
 0.001). Serum stimulated MCP-1
production by both TSC fibroblasts and angiofibroma cells
(P 
 
 
 
 0.001), but the effect was greater in angiofibroma cells
(P 
 
 
 
 0.001; Fig. 4).
To test biological activities of MCP-1 produced by TSC
tumor cells, we performed proliferation and chemotaxis as-
says. Proliferation of normal human fibroblasts, TSC fibro-
Figure 2. Cells cultured from TSC skin tumors express the fibroblast 
marker HSP47 but not CD68. The cytoplasm of TSC fibroblasts (A) and 
angiofibroma cells (B) stain positive for HSP47 (green), whereas U937 cells 
(C), a human monocytic cell line, are negative. In contrast, the cytoplasm 
of TSC fibroblasts (D) and angiofibroma cells (E) are negative for CD68, and 
the cytoplasm of U937 cells (F) stains positive (green). Nuclei fluoresce 
blue with DAPI. Bar, 15  m. Similar results were observed in cells from 
two other patients.
Figure 3. Measurement of cytokines in culture supernatants reveals 
increased production of MCP-1 by angiofibroma cells. Fibroblasts from 
normal-appearing skin (NL) or angiofibroma cells (AF) from seven patients 
were incubated in 1% FBS/DMEM for 24 h, and supernatants were collected 
for cytokine measurement using ELISA. Lines connect paired samples for 
each patient. The inset shows the data as a box plot. *, P   0.018.
 
Table I.
 
Cells derived from angiofibromas and periungual 
fibromas express higher levels of MCP-1 mRNA and protein 
than do fibroblasts from the same patient
 
MCP-1
Patient Tumor
 
mRNA
 
a
 
Protein
 
b
 
ratio: tumor/normal
 
c
 
1
AF 33 15
PF 2.1 1.7
2A F 1 2 1 9
3 AF 6.4 6.0
4
AF 1.3 1.4
PF 2.0 1.4
5
AF 4.5 1.9
PF 2.9 2.0
6 PF 4.9 4.1
7
AF1 1.6 3.9
AF2 31 104
8A F 2 0 3 2
9
AF 2.9 3.5
PF 1.8 3.2
10 AF 5.2 15
 
a
 
Real-time PCR was used to measure MCP-1 mRNA levels in triplicate. Results were 
normalized to 18S rRNA, and results were expressed as a ratio of angiofibroma or 
periungual fibroma to TSC fibroblasts.
 
b
 
An ELISA was used to measure MCP-1 in culture supernatants in triplicate. Results 
were normalized by total cellular protein and expressed as a ratio of tumor to normal.
 
c
 
Equal numbers of cells were incubated for 24 h in DMEM plus 1% FBS.
 AF, angiofibroma; PF, periungual fibroma. 
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blasts, and angiofibroma cells was similar whether growing in
conditioned medium from angiofibroma cells (containing
740 pg/ml MCP-1) or from TSC fibroblasts (containing 44
pg/ml MCP-1; unpublished data). Likewise, recombinant
MCP-1 (1,000 pg/ml) had no significant effect on prolifera-
tion of these cells (unpublished data). Thus, MCP-1 did not
seem to be a major mitogen for angiofibroma cells, but
MCP-1 produced by angiofibroma cells did stimulate che-
motaxis of THP-1 cells, a human monocytic cell line. THP-1
cell migration in response to conditioned medium from an-
giofibroma cells was greater than migration in response to
medium from TSC fibroblast alone (P 
 
 
 
 0.019) or plus con-
trol IgG (P 
 
 
 
 0.007), whereas the addition of neutralizing
antibody to MCP-1 abrogated the effect on migration (Fig.
5). Findings were similar using recombinant MCP-1 (5 ng/
ml) as a positive control: IgG had no effect, and anti-MCP-1
antibody blocked chemotactic activity (unpublished data).
Thus, MCP-1 produced by angiofibroma cells may play a
significant role as a chemotactic factor, recruiting cells into
the tumor.
 
Overexpression of MCP-1 by tuberin-null rat fibroblasts 
is inhibited by 
 
TSC2
 
 transfection or inhibition of 
mTOR signaling
 
To investigate the relationship between MCP-1 production
and tuberin function in a homogeneous, genetically defined
cell population, we compared EEF 
 
Tsc2
 
 
 
/
 
 
 
 cells with those
expressing tuberin (EEF 
 
Tsc2
 
 
 
/
 
 
 
). EEF 
 
Tsc2
 
 
 
/
 
 
 
 cells pro-
duced significantly more MCP-1 than did EEF 
 
Tsc2
 
 
 
/
 
 
 
 cells
(P 
 
 
 
 0.01 at all times tested; Fig. 6). To evaluate further
whether loss of tuberin leads to increased MCP-1 production,
we transiently transfected EEF 
 
Tsc2
 
 
 
/
 
 
 
 cells with full-length
human 
 
TSC2
 
 cDNA constructs including one WT, two hu-
man polymorphisms, and two mutants identified in TSC pa-
tients (19). Under conditions that yielded a transfection effi-
ciency of 50% for GFP (unpublished data), transfection with
WT tuberin or two nonpathogenic missense polymorphisms
(M286V and R367Q) decreased MCP-1 production by
 
 
 
50% (P 
 
 
 
 0.005; Fig. 7). A dose-response for transfection
with WT tuberin showed that tuberin significantly inhibited
MCP-1 production in a dose-dependent manner (Fig. 7). In
contrast, two nontruncating mutants (G294E and I365del)
known to disrupt binding of tuberin to hamartin (19) had no
effect on MCP-1 production (Fig. 7). Because tuberin nega-
tively regulates signaling through the PI3K-Akt-TSC1/2-
Figure 4. MCP-1 production is stimulated by FBS. Paired cultures of 
angiofibroma cells (AF) and TSC fibroblasts (NL) from two patients were 
seeded at 10,000 cells/well in 96-well plates, in DMEM containing 0%, 1%, 
2%, or 10% FBS (1% BSA was added to the 0% FBS condition). After a 12-h 
incubation, MCP-1 concentration in the medium was measured by ELISA 
(pg/ml), and expressed per total cellular ATP (luminescence units) as an 
indication of cell number. Results are means   SD of values from triplicate 
wells. Fresh medium with 10% FBS does not contain detectable MCP-1.
Figure 5. MCP-1 produced by TSC tumor cells is chemotactic for 
monocytes. Conditioned medium (CM), from TSC fibroblasts (closed bars) 
or angiofibroma cells (open bars), CM plus control antibody, or CM plus 
anti-MCP-1 antibody was added to the bottom chamber of cell migration 
plates. THP-1 cells (a human monocytic cell line) were added to the top 
chamber. Cells that migrated through 8- m pores to the feeder tray after 
a 2-h incubation were lysed and detected by CyQuant GR dye that exhibits 
enhanced fluorescence upon binding cellular nucleic acids. Results are 
geometric means   SD of values from three separate migration chambers. 
*, P   0.019 and **, P   0.007 as compared with CM from TSC fibroblasts. 
Conditioned medium from angiofibroma cells or TSC fibroblasts contained 
1640 and 60 pg/ml MCP-1, respectively. Similar results were observed in 
three separate experiments.
Figure 6. EEF Tsc2 /  fibroblasts produced more MCP-1 than normal 
(EEF Tsc2 / ) fibroblasts. Culture supernatants were collected after 
incubating EEF cells for the indicated time, and MCP-1 in the medium was 
measured by ELISA. Results are means   SD of triplicate supernatants. 
JEM VOL. 202, September 5, 2005
 
621
 
ARTICLE
 
Rheb-mTOR pathway, we tested the effects of pharmaco-
logical inhibition of this pathway on MCP-1 production by
EEF 
 
Tsc2
 
 
 
/
 
 
 
 cells. The inhibitors used were rapamycin, a
specific inhibitor of mTOR, FTI-277, a farnesyl transferase
inhibitor that blocks production of active Rheb, and
LY294002, a PI3K and mTOR inhibitor. Each of these com-
pounds significantly suppressed MCP-1 production in a con-
centration-dependent manner (
 
*
 
, P 
 
 
 
 0.01; Fig. 8). None of
the compounds was cytotoxic at the concentrations tested
(unpublished data). Thus, overexpression of MCP-1 by EEF
 
Tsc2
 
 
 
/
 
 
 
 cells was mTOR-dependent.
 
DISCUSSION
 
The cellular composition of TSC tumors is mixed, implicat-
ing paracrine factors in their development. Previous studies
have focused on the increased vessels in TSC tumors and
have shown increased expression of VEGF (7, 9–12). We
found that TSC skin tumors, in addition to having more
blood vessels and fibrosis than normal skin, show greater
numbers of CD68-positive cells, and that cells derived from
TSC skin tumors overexpress MCP-1, a chemokine with
roles in angiogenesis, fibrosis, and recruitment of monocytes.
We also showed that conditioned medium from cultured
TSC skin tumor cells was chemotactic for human monocytic
cells, and neutralizing antibody against MCP-1 inhibited the
chemotactic activity. These data suggest that MCP-1 is a
paracrine factor that contributes to TSC tumorigenesis.
MCP-1 and its receptor, CCR2, are expressed by a vari-
ety of cells including skin fibroblasts, and are up-regulated in
a variety of pathological processes (20, 21). MCP-1 expres-
sion has been associated with tumor vascularity (22) and is
critical for hemangioendothelioma proliferation (23). MCP-1
can stimulate angiogenesis directly (24) and indirectly
through recruitment of monocytes (25). MCP-1 is overex-
pressed in fibrotic processes and has a variety of fibrogenic ef-
fects (21, 26, 27). Thus, it is likely that MCP-1 overexpres-
sion in TSC skin tumors stimulates angiogenesis and fibrosis.
MCP-1 is chemotactic for monocytes and for peripheral
blood myeloid DCs (28). Expression of MCP-1 is associated
with the appearance of tumor-associated macrophages (29)
and with recruitment of DCs into skin (30). It has been pro-
posed that mononuclear phagocytes both stimulate tumor for-
mation through effects on angiogenesis and release of mito-
gens and, in other systems, inhibit tumor growth through
immunologic effects (29). In TSC skin tumors, the balance of
growth-promoting and growth-inhibitory effects of tumor-
associated mononuclear phagocytes may lead to the long-term
stable size of cutaneous tumors. Disruption of this balance
may represent a new therapeutic approach for these tumors.
TSC skin tumors are heterogeneous in cell lineages and
genetically. Although it has been possible to show loss of
heterozygosity (LOH) at the 
 
TSC2
 
 locus in other TSC tu-
mors, angiofibromas and periungual fibromas often do not
show LOH (31), probably because of the mixture of
Figure 7. Transfection of WT but not mutant TSC2 into EEF Tsc2 /  
cells inhibits MCP-1 production. EEF Tsc2 /  cells were transfected 
with the indicated amounts of human TSC2 constructs and/or empty vector. 
In the last lane, EEF Tsc2 /  cells were transfected with empty vector. After 
transfection, cells were maintained in DMEM with 10% FBS overnight before 
the culture medium was replaced with DMEM containing 2% FBS; then 
incubation continued for an additional 24 h. The cells were harvested, and 
tuberin expression was detected by Western blot. Culture supernatants 
were collected, and MCP-1 release into the medium was measured by 
ELISA. Results are the mean   SD of three separate wells. M1, mutation 
G294E; M2, mutation I365del; P1, polymorphism M286V; P2, polymor-
phism R367Q. *P,   0.01 compared with empty vector control. Similar 
results were obtained in three separate experiments.
Figure 8. MCP-1 production by EEF Tsc2 /  cells is inhibited by 
rapamycin, FTI-277, and LY294002. Rat MCP-1 was measured in culture 
supernatants by ELISA after incubating equal numbers of cells 24 h in serum-
free medium without or with inhibitor at the indicated concentration. MCP-1 
concentration was expressed per total secreted protein at the end of the 
incubation and is reported as the mean   SD of triplicate wells. *, P   0.01 
compared with control. Similar results were obtained in three separate 
experiments.MCP-1 OVEREXPRESSION IN TSC SKIN TUMOR CELLS | Li et al. 622
TSC2 /  cells and TSC2 /  cells in such lesions. Immuno-
histochemical studies of hamartin and tuberin expression are
consistent with this interpretation. When loss of hamartin
and tuberin expression is observed in angiofibromas, the cells
showing decreased staining are the interstitial cells, not en-
dothelial cells (32). We have not detected LOH in our cul-
tured angiofibroma cells or periungual fibroma cells, in
agreement with the results of others (33). However, most of
these cultures show allelic deletion of the TSC2 gene in a
minority of the cells (34). In addition, angiofibroma cells and
periungual fibroma cells exhibit hyperphosphorylation of ri-
bosomal protein S6 under conditions of serum starvation
(35), which is also observed in other TSC-related tumors as
a consequence of loss of tuberin function and activation of
mTOR signaling. Together, these observations suggest that
increased MCP-1 production by these angiofibroma cells
and periungual cells is related to defective tuberin function,
although the possibility of additional genetic or epigenetic
alterations cannot be excluded.
To explore the relationship of defective tuberin function
and MCP-1 production, we used EEF Tsc2 /  cells. Much
more MCP-1 was produced by EEF Tsc2 /  cells than by
EEF Tsc2 /  cells. MCP-1 production by EEF Tsc2 /  cells
was reduced by transient transfection with human tuberin and
was suppressed by rapamycin, a specific inhibitor of mTOR.
These results indicate that MCP-1 overexpression by EEF
Tsc2 /  cells is caused by defective tuberin function and dys-
regulated mTOR-dependent signaling. Recently, it was
shown that transgenic mice overexpressing a dominant-nega-
tive allele of tuberin develop fibrovascular collagenomas in the
skin, and that these skin lesions show increased expression of
MCP-1 as compared with WT skin (36). Others have found
that rapamycin inhibits MCP-1 production in animal models
of atherosclerosis (37) and transplant rejection (38, 39). It is in-
teresting that loss of tuberin function and increased activation
of the Rheb/mTOR/S6K pathway induce insulin receptor
substrate-1 depletion and insulin resistance (40, 41), and that
baseline levels of MCP-1 are increased in insulin-resistant
3T3-L1 adipocytes and in insulin-resistant obese mice (42).
In conclusion, MCP-1 is overexpressed by TSC skin tumor
cells and probably exerts paracrine effects leading to angiogene-
sis, fibrosis, and recruitment of monocytes. Blocking MCP-1
has been effective for treatment of a variety of conditions in ex-
perimental animals, including atherosclerosis (43), pulmonary fi-
brosis (27), and renal fibrosis (26), and antibodies to MCP-1
completely blocked the development of hemangioendothelio-
mas in mice (44). Therefore, MCP-1 may present a new thera-
peutic target for TSC skin tumors in humans.
MATERIALS AND METHODS
Tumor samples and cell culture. Adult patients, diagnosed with TSC
according to clinical criteria (45) were enrolled after institutional review
board approval (National Heart, Lung, and Blood Institute Institutional Re-
view Board–approved protocol 00-H-0051). Cells cultured from explants
of angiofibromas, periungual fibromas, and patients’ normal-appearing skin
as previously described (14), from normal adult human fibroblasts (Cambrex
Bio Science), and from EEF Tsc2 /  and EEF Tsc2 /  cells (46) were
grown in DMEM supplemented with 10% FBS, penicillin (100 U/ml) and
streptomycin (100  g/ml). Human monocyte cell lines U937 and THP-1
(ATCC), were grown in RPMI 1640 medium with 10% FBS.
Immunohistochemical and immunocytochemical staining. 6- m
sections of four angiofibromas, four periungual fibromas, and four samples
of normal-appearing skin from six patients were immunostained using the
autostainer (DakoCytomation) according to the manufacturer’s recommen-
dations with antibodies against S100 (1:600), HMB-45 (1:50), smooth mus-
cle actin (1:200), CD34 (1:75), CD68 (1:200), vimentin (1:200) (DakoCy-
tomation) and factor XIIIa (Bio-Genex). An avidin-biotin peroxidase
detector kit (DakoCytomation) was used with diaminobenzidine as the
chromogen and Gill’s hematoxylin as the counterstain.
TSC fibroblasts, angiofibroma cells, or human monocytic cells (5  104
cells per chamber) on four-chamber slides (Nalge Nunc International) were
incubated overnight in DMEM plus 10% FBS, followed by DMEM plus
1% FBS for 24 h. After fixation, permeabilization, and blocking, cells were
incubated with mouse anti-Hsp47 monoclonal antibody (3  g/ml; Stress-
Gen Biotechnologies), anti-CD68 monoclonal antibody (1:100 dilution;
DakoCytomation), Texas red  -smooth muscle actin (1:100; Sigma-
Aldrich), or HMB45 (1:25; DakoCytomation) overnight at 4 C, and then
with Alexa Fluor 488 goat anti–mouse IgG (1:1,000; Molecular Probes) at
room temp for 1 h before nuclei were stained with DAPI.
Gene expression arrays. Early-passage human cells (P   3–5) were
grown until 70–80% confluent. The medium was changed to DMEM plus
1% FBS 24 h before harvesting. Total RNA was extracted from primary
cultured cells using a phenol-based kit (TRIzol, GIBCO BRL), followed
by further purification using an RNeasy Midi-Column (QIAGEN) and
concentration using Microcon YM-30 (Millipore). Radiolabeled cDNA
probes, made using a gene-specific primer mix and [33P]dATP, were hy-
bridized to the Clontech Atlas Human Cytokine/Receptor Array (BD Bio-
sciences), according to manufacturer’s instructions. To quantify signal in-
tensity, a phosphorimager (Storm 860, Molecular Dynamics, Inc.) was used
at a pixel resolution of 100  m. These data were analyzed using P-SCAN
(peak quantification using statistical comparative analysis) software, version
1.2 and MATLAB 6.1 (The MathWorks, Inc.).
Culture supernatant cytokine array. Human cells (5   105 cells/well)
were incubated overnight on six-well plates in 10% FBS/DMEM. The me-
dium was switched to 1% FBS/DMEM, and the cells were incubated for 24 h.
The levels of 11 cytokines (MCP-1, VEGF, platelet-derived growth factor-bb,
TNF , fibroblast growth factor, IL-7, IL-8, GM-CSF, lymphotaxin, IFN- –
inducible T cell   chemoattractant, and leukemia inhibitory factor) were mea-
sured in supernatants using a multiplexed ELISA (SearchLight Array).
Human MCP-1 mRNA and protein. Human cells (1  106 cells/plate)
were grown overnight on 10-cm plates in 10% FBS/DMEM, then were
switched to 1% FBS/DMEM, and the incubation was continued for 24 h.
Supernatants were collected, and total RNA was extracted from the cells
using the RNeasy Mini Kit (QIAGEN). MCP-1 mRNA and 18S rRNA
were measured using RT PCR with MCP-1 or 18S rRNA primers and
FAM dye-labeled probe (MCP-1, 18S rRNA; Assays-on-Demand, Applied
Biosystems) on an ABI PRISM 5700 Sequence Detection System Instru-
ment (Applied Biosystems). MCP-1 was measured in supernatants using an
ELISA specific for human MCP-1 (R&D Systems). Cellular lysates were
prepared in 10 mM Tris buffer, pH 7.4, 100 mM NaCl, 1% Triton X-100,
10% glycerol, 0.1% SDS, 1 mM PMSF and a mixture of protease inhibitors
(Sigma-Aldrich). Total cellular protein was measured using BCA reagent
(Pierce Chemical Co.).
Proliferation and chemotaxis assays. Cells (1,500 cells/well in 96-well
plates) were incubated overnight in 10% FBS/DMEM, before the medium
was changed to 1% BSA/DMEM (no serum) with or without MCP-1 (1
ng/ml) (Pepro Tech) or 2% FBS/DMEM. Cells were incubated for 72 h,JEM VOL. 202, September 5, 2005 623
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with medium changed every 24 h. Cell number was assessed by measuring
cellular ATP content with a luminescence assay (ATPlite, PerkinElmer) and
BMG FLUOstar plate reader (BMG Lab Technologies). For preparation of
conditioned medium, TSC fibroblasts or angiofibroma cells in 10-cm dishes
(1   106 cells/dish) were incubated overnight in 10% FBS/DMEM before
the medium was replaced with 1% FBS/DMEM and incubation continued
for an additional 24 h. Culture supernatants were then collected and stored
at  70 C.
Monocyte chemotaxis was assayed using Chemicon QCM 96-well cell
migration assay (8- m pore size) (CHEMICON International, Inc). THP-1
cells were incubated in 1% FBS/DMEM for 24 h before transferring 1.5  
105 cells/100  l of the same medium to migration chambers. Conditioned
medium (150  l/well) was added to the feeder tray. Recombinant human
MCP-1 was used as the positive control. In neutralization studies, the con-
ditioned medium was incubated with 10  g/ml of either anti-human
MCP-1 monoclonal antibody (R&D Systems) or control mouse IgG (R&D
Systems) for 2 h at 4 C before use in chemotaxis assays.
Rat MCP-1. Rat embryonic fibroblasts (5   105 cells/well) were grown
overnight on six-well plates in 10% FBS/DMEM before switching to 2%
FBS/DMEM, and the incubation continued for the indicated time. Rat
MCP-1 was measured in culture medium by ELISA (Pierce Chemical Co.).
Gene transfection. Rat EEF Tsc2 /  cells were transfected with WT
TSC2, mutant TSC2, or TSC2 polymorphism in pCMVTag2 (J. Sampson,
Cardiff, UK) or with the empty vector by nucleofection technology using
MEF Nucleofector kits (Amaxa Biosystems) according to the manufac-
turer’s instructions. After transfection, cells were maintained in DMEM
with 10% FBS overnight before the culture medium was replaced with
DMEM containing 2% FBS, and incubation continued for an additional
24 h. Culture supernatants were collected for assay of MCP-1 by ELISA.
Cells were lysed, and cell lysates were subjected to SDS-PAGE and immuno-
blotting for tuberin using rabbit anti-tuberin C-20 (Santa Cruz Biotechnol-
ogy, Inc.) and monoclonal anti- -actin antibody AC-15 (Sigma-Aldrich).
Cell treatment. Rat embryonic fibroblasts plated in 12-well plates (2  105
cells/well) were incubated in 10% FBS/DMEM overnight before incubation
for 4 h with serum-free DMEM containing indicated concentrations of ra-
pamycin (EMD Biosciences, Inc.), FTI-277 (EMD Biosciences, Inc.), or
LY294002 (BIOMOL Research Laboratories, Inc.), followed by an addi-
tional 24 h in fresh medium with the same inhibitor. Cell culture superna-
tants were collected, and MCP-1 was quantified by ELISA. The concentra-
tions of total secreted proteins in cell culture supernatants were quantitated
by Bio-Rad Protein Assay (Bio-Rad Laboratories). Cell death was measured
by lactate dehydrogenase release with the CytoTox96 Non-Radioactive Cy-
totoxicity Assay (Promega) according the manufacturer’s instructions.
Statistics. Cytokine ELISA data were analyzed using Wilcoxon signed
ranks test. MCP-1 mRNA and protein data were analyzed using a one-
sample t test to compare the average log ratio of fold-changes to the hy-
pothesized value of 0 (no difference). The effects of serum on MCP-1 pro-
duction by fibroblasts and angiofibroma cells from individuals with TSC
were assessed using univariate analysis of variance. Overall significance of
the effects of transfections or pharmacological agents on MCP-1 production
was evaluated using analysis of variance, followed by Dunnett t test to com-
pare each treatment group to control. For all other comparisons, signifi-
cance was determined using t test with equal variances not assumed. Signifi-
cance was defined as P   0.05.
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